Free Trial

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Should You Sell?

Ascentage Pharma Group International logo with Medical background

Key Points

  • Ascentage Pharma Group International shares experienced a significant gap down, opening at $39.82 after closing at $41.95.
  • Chevy Chase Trust Holdings LLC recently acquired a new stake in Ascentage with 5,753 shares valued at approximately $227,000, according to a 13F filing.
  • The company, a clinical-stage biotechnology firm, focuses on developing therapies for cancers, hepatitis B virus, and age-related diseases.
  • Want stock alerts on Ascentage Pharma Group International? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $41.95, but opened at $39.82. Ascentage Pharma Group International shares last traded at $39.80, with a volume of 1,387 shares trading hands.

Ascentage Pharma Group International Price Performance

The firm's 50 day simple moving average is $37.88. The company has a debt-to-equity ratio of 3.24, a quick ratio of 1.26 and a current ratio of 1.26.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at $227,000. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Tema Etfs LLC acquired a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at $610,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Ascentage Pharma Group International during the 1st quarter valued at $3,511,000.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Recommended Stories

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines